All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection

Citer cette référence
WYLES, D. L., RODRIGUEZ-TORRES, M., LAWITZ, E., SHIFFMAN, M. L., POL, S., HERRING, R. W., MASSETTO, B., KANWAR, B., TRENKLE, J. D., PANG, P. S., ZHU, Y., MO, H., BRAINARD, D. M., SUBRAMANIAN, G. M., MCHUTCHISON, J. G., HABERSETZER, Francois et SULKOWSKI, M. S., 2014. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection. Hepatology. 2014. Vol. 60, n° 1pp. 56-64. DOI 10.1002/hep.27053.